Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.49 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.49 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 10/20 | 0.96 |
| ▸ | DRD3 | P35462 | 10/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 6/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL354391 | 1.00 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTKDM4E | |
| Bromide SCHEMBL5722309 | 1.00 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTKDM4E | |
| SCHEMBL265949 | 0.98 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTKDM4E | |
| SCHEMBL30697493 | 0.98 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTKDM4E | |
| SCHEMBL9135070 | 0.98 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTKDM4E | |
| SCHEMBL5722322 | 0.98 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTKDM4E | |
| SCHEMBL30839518 | 0.98 | DRD2 (1.00) | DRD2DRD3OPRK1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL9317222 | 0.96 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTKDM4E | |
| Water SCHEMBL9305270 | 0.96 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTKDM4E | |
| Water SCHEMBL9305264 | 0.96 | DRD2 (0.96) | DRD2DRD3OPRK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-0893432-B1 | PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-0988296-B1 | NAPHTHOTHIAZOLONE DERIVATIVES ACTIVE ON THE D 3 DOPAMINERGIC RECEPTOR | ZAMBON SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| EP-0882704-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6133266-A | 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6107318-A | PSYCHOLOGICAL DISORDERS | ZAMBON GROUP S.P.A. (IT) | 2000-08-22 | — | — | US | disclosed |
| US-6046192-A | Phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0988296-A1 | NAPHTHOTHIAZOLONE DERIVATIVES ACTIVE ON THE D 3 DOPAMINERGIC RECEPTOR | ZAMBON GROUP S.p.A. (IT) | 2000-03-29 | — | — | EP | disclosed |
| EP-0893432-A1 | PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | Kissei Pharmaceutical Co. Ltd. (JP) | 1999-01-27 | — | — | EP | disclosed |
| WO-1998056778-A1 | NAPHTHOTHIAZOLONE DERIVATIVES ACTIVE ON THE D3 DOPAMINERGIC RECEPTOR | ZAMBON GROUP S.P.A. (IT) | 1998-12-17 | — | — | WO | disclosed |
| EP-0882704-A1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5312961-A | 2-amino-7-hydroxytetralin carboxylalkyl ethers | ELF SANOFI (FR) | 1994-05-17 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| US-5235103-A | Process for the preparation of phenylethanolaminotetralins | SANOFI (FR) | 1993-08-10 | — | — | US | disclosed |
| US-5202466-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1993-04-13 | — | — | US | disclosed |
| US-5198586-A | Process for the preparation of phenylethanolaminotetralins | SANOFI (FR) | 1993-03-30 | — | — | US | disclosed |
| US-5159103-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1992-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | ACHE 3488/4885HTR1A 868/4885ADRB2 2363/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | ACHE 1462/4885HTR1A 382/4885ADRB2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.